- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
First Results of Collaboration Between Veridex, LLC and Massachusetts General Hospital Published in Science Translational Medicine
U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes
INVOKANA™ is the first in a new class of type 2 diabetes medications available in the United States In Phase 3 studies, INVOKANA™ improved blood glucose control and was associated with reductions in body weight and systolic blood pressure Janssen will partner with other Johnson & Johnson companies focused on diabetes to bring INVOKANA™ to healthcare professionals
Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
Filing Based on Phase 3 Data in Treatment-Naïve and Treatment-Experienced Patients with Compensated Liver Disease
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Program Further Extends XARELTO® as the Most Studied New Oral Anticoagulant in the World Today
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
Investigational oncology agent for B-cell malignancies jointly being developed by Janssen and Pharmacyclics